IatroQuest receives $4.8 million in financing


IatroQuest Corp has received a $4.8-million private placement to further develop its Bio-Alloy technology platform for the detection of biological and chemical agents. The financing was provided by Investissement Desjardins ($1.5 million), Business Development Bank of Canada ($1.5 million) T2C2 Bio 2000 ($1 million) and several private investors ($800,000). IatroQuest is a spin-off of the National Research Council, with the assistance of the Ottawa branch of Inno-Centre. The Ottawa firm’s Bio-Alloy is a ‘bio-photonic’ technology that uses biosensing modules (including micro-array biochip formats) to detect bacteria, viruses and toxins in real-time with a high degree of sensitivity. It will be aiming its OEM products at military, civilian and medical markets. Iatro-Quest has appointed Jean Bourbonnais as its new president and CEO, taking over from co-founders Dr David Armstrong (executive VP innovation and regulatory affairs) and Dr Martine Lafrance (chief technology officer)....


Other stories mentioning these organizations, people and topics
Organizations:

Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.